期刊
BLOOD
卷 113, 期 2, 页码 291-298出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-04-153239
关键词
-
类别
资金
- Dutch Cancer Society Koningin Wilhelmina Fonds (Amsterdam, The Netherlands)
- National Institutes of Health (Bethesda, MD) [CA118316]
The past decade has shown a marked increase in the use of high-throughput assays in clinical research into human cancer, including acute myeloid leukemia (AML). In particular, genome-wide gene expression profiling (GEP) using DNA microarrays has been extensively used for improved understanding of the diagnosis, prognosis, and pathobiology of this heterogeneous disease. This review discusses the progress that has been made, places the technologic limitations in perspective, and highlights promising future avenues. (Blood. 2009;113:291-298)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据